Research programme: CCR5 receptor antagonists - CytoDyn
Latest Information Update: 28 Jun 2020
Price :
$50 *
At a glance
- Originator ProstaGene
- Developer CytoDyn; Sidney Kimmel Cancer Center
- Class Antineoplastics; Antivirals; Small molecules
- Mechanism of Action CCR5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer; Prostate cancer
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for preclinical development in Breast-cancer in USA (PO)
- 28 Jun 2020 No recent reports of development identified for preclinical development in Prostate-cancer in USA (PO)
- 19 Nov 2018 ProstaGene has been acquired and merged into CytoDyn